Objective: The Prostate Cancer Risk Index (PRIX) is a simple scoring system for risk stratification of clinically localized prostate cancer that relies on three variables: prostate-specific antigen level at diagnosis, Gleason score at biopsy and clinical T stage. The aim of this study was validation of the ability of the PRIX score to predict biochemical relapse after radical prostatectomy in a series of patients from a single Japanese center. Methods: From 1995 to 2008, 519 patients who underwent radical prostatectomy for clinically localized prostate cancer with no adjuvant therapies were included in the validation cohort. The biochemical relapse-free rate was estimated using the Kaplan -Meier method. The performance of the PRIX score was assessed with Cox proportional hazards regression model, concordance index and a calibration plot. For comparison, the performance of the D'Amico classification was also assessed. Results: Biochemical relapse-free rate continuously decreased as the PRIX score increased. Each 1-point increment in the PRIX score led to an increase in hazard ratio for biochemical relapse. The concordance index of the PRIX score and the D'Amico classification to predict biochemical relapse was 0.719 and 0.730, respectively. The Kaplan -Meier plots and the calibration plots demonstrated the possibility that the PRIX score could present more detailed stratification than the D'Amico classification.
INTRODUCTION
Radical prostatectomy (RP) is an established treatment modality for localized prostate cancer. However, biochemical relapse (BCR) occurs in 15 -30% of patients within 5 years after RP (1, 2) . The probability of BCR varies according to preoperative characteristics such as preoperative prostatespecific antigen (PSA) level, Gleason score at biopsy and clinical T stage. During the last two decades, various models have been developed to predict BCR after RP by combining these preoperative characteristics on the basis of statistical analyses such as the D'Amico risk classification (3) , the Cancer of the Prostate Risk Assessment (CAPRA) score (4) and the Stephenson nomogram (5), as well as other available prediction tools. There are differences among the characteristics of each of these prediction tools. Reasonably, the more complex a prediction tool is, the more accurately the model predicts outcomes. However, excessively complex models such as a nomogram are clearly impractical in a busy environment. Conversely, risk classifications such as the D'Amico risk classification are very simple and useful but have considerable within-group heterogeneity in outcomes.
The Prostate Cancer Risk Index (PRIX) was developed by Yoshioka et al. (6, 7) and is a simple scoring system for risk stratification of clinically localized prostate cancer that relies on three variables: PSA level at diagnosis, Gleason score at biopsy and clinical T stage. The PRIX score categorizes each variable, and each is assigned a score of 0 -2. The PRIX score is a straightforward 0 -6 sum of these weighted variables. The PRIX score can be easily calculated without the need for a calculator or printed table. In the original report of Yoshioka and Inoue (6), the PRIX score was shown to fully correspond to the Partin et al. table (8) in terms of pathological lymph node involvement and to correspond to the Kattan nomogram (9) better than did the D'Amico risk classification. Thus, the PRIX score is hypothesized to function as a risk prediction tool for clinically localized prostate cancer. However, the PRIX score has not yet been fully validated in any actual cohort. Therefore, the aim of this study was to validate the ability of the PRIX score to predict BCR after RP in a series of patients treated at a single Japanese tertiary care center.
PATIENTS AND METHODS

PATIENT POPULATION
A retrospective search of the prostate cancer database at the Osaka Medical Center for Cancer and Cardiovascular Disease (OMCC) identified 691 patients who underwent retropubic RP and limited pelvic lymph node dissection for clinical T1c-T4N0M0 prostate cancer at OMCC between January 1995 and December 2008. Of these patients, 128 were excluded because their Gleason scores at biopsy were not available. Of the 563 remaining patients with data consistent with the requirements of the PRIX scoring system, 44 were excluded for the following reasons: 18 underwent adjuvant radiation, 5 underwent adjuvant hormonal therapy, 3 underwent concurrent surgical castration and in 18 patients, postoperative follow-up information was not available. Ultimately, 519 patients were included in the validation cohort.
POSTOPERATIVE EVALUATION
The postoperative follow-up protocol consisted of a PSA measurement at 1 month after RP, with subsequent PSA measurements every 3 months for the first 2 years, semiannually for the third year and annually thereafter. BCR was defined as a PSA level of 0.2 ng/ml followed by a second PSA level higher than the first separated by at least 4 weeks or the initiation of salvage radiotherapy or hormonal therapy for the postoperative PSA elevation. If the postoperative nadir PSA level was found to be 0.2 ng/ml, the date of BCR was defined as the date of RP (defined as BCR at Day 0).
DEFINITON OF THE PRIX SCORE
The definition of the PRIX scoring system is summarized in Table 1 . The PRIX score, which ranges from 0 to 6, was previously reported as a scoring system for risk classification of clinically localized prostate cancer (6, 7) . In this scoring system, a score of 0 points is assigned to a PSA level at diagnosis of ,10.0 ng/ml, 1 point to a PSA of 10.0 -20.0 ng/ml and 2 points to a PSA of 20.0 ng/ml. Gleason scores at biopsy of 6, 7 and 8 are assigned 0, 1 and 2 points, respectively. Clinical stages T1-T2a, T2b-T2c and T3-T4 are similarly assigned 0, 1 and 2 points, respectively. Clinical T stage is classified according to the 2002 TNM classification by digital rectal examination. Findings of magnetic resonance imaging or computed tomography were not considered for evaluation of clinical T stage in the present analysis. The sum of these three scores equals the PRIX score.
STATISTICAL ANALYSES
Because of the small number of patients with a PRIX score of 4, 5 or 6, the patients with one of these three scores were combined for analysis. The BCR-free rate was estimated using the Kaplan -Meier method. Differences between the BCR-free rates in relation to individual factors were compared using the log-rank test. The performance of the PRIX score for prediction of BCR was assessed with the Cox proportional hazards regression model. The accuracy of the PRIX score for prediction of BCR was quantified according to Harrell's concordance (c) index. A c-index of 1.0 indicates perfect prediction, and an index of 0.5 indicates no relation. Subsequently, a calibration plot was developed for For the comparative analysis, the performance of the D'Amico risk classification in the present cohort was also assessed in the same manner.
All statistical analyses were performed with R v2.12.1.
RESULTS
The clinical characteristics of the 519 patients in the validation cohort are summarized in The distribution of the PRIX score for the patients in the validated cohort from the OMCC database and the number of patients with BCR are summarized in Table 3 . In the present cohort, the vast majority had a PRIX score between 0 and 4. Of the 519 patients, 103 (19.8%) patients developed BCR within a median of 13.0 months (range, 0 -74.1 months); 73 (70.9%) of these patients with BCR failed according to PSA criteria and 30 (29.1%) because of salvage treatment. NHT before RP did not provide any advantage in BCR-free rate over RP alone (P ¼ 0.861, log-rank test).
The actual 3-and 5-year BCR-free rates according to the PRIX score are summarized in Table 4 . The BCR-free rate continuously decreased as the PRIX score increased. The plot of the actual BCR-free rate according to the PRIX score is shown in Fig. 1A . A Cox proportional hazards regression model was developed to predict BCR using the PRIX score (Table 4) . Each 1-point increment in the PRIX score led to an increase in hazard ratio for BCR in the present cohort. The c-index of the PRIX score to predict BCR was 0.719. Using 200 bootstrap samples, the calibration plot shows predicted and actual BCR-free rates at 5 years in Fig. 2A . The calibration plot demonstrates that the PRIX score is generally well calibrated. The PRIX score predictions applied to patients with BCR-free rates that ranged from 46.0 to 89.9% at 5 years.
The calibration plot demonstrates that the D'Amico risk classification is generally well calibrated (Fig. 2B) . The D'Amico risk classification predictions applied to patients with BCR-free rates that ranged from 61.7 to 89.9% at 5 years. Compared with the D'Amico risk classification, the PRIX score allowed the wider range of predictions.
DISCUSSION
Prediction models are usually developed on the basis of statistical analysis of the outcome in a specific cohort. Then, these models are validated internally or externally. In this regard, the PRIX score is a unique risk prediction model because the PRIX score was not developed on the basis of the statistical analysis of a specific cohort but was developed solely on the basis of correspondence to the other prediction models (6) . Therefore, internal validation of the PRIX score cannot be performed, and external validation is required; so far, however, the PRIX score has not been externally validated. In this study, we externally validated the PRIX score for the prediction of BCR after RP and showed that the PRIX score accurately predicted BCR after RP in Japanese patients treated at a single center. The prediction models combining preoperative characteristics range in complexity from a three-level categorization to the nomogram. It is reasonable to expect that the more complex a prediction tool is, the more accurately it predicts outcomes in detail. Such excessively complex models like nomograms are clearly impractical in a busy environment because a multi-step paper tool or a computer program is required. A scoring system such as the PRIX score offers easier calculation and application than those of the Stephenson nomogram but provides more detailed and accurate risk stratification data than those of the D'Amico risk classification. However, Shariat et al. (10) have claimed that scoring systems such as that of the PRIX should be avoided because they assume that each variable exerts an equal prognostic weight on the outcome, which is unlikely to represent the true relation between variables and prognosis. 
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Although the usefulness of the D'Amico risk classification for clinically localized prostate cancer is well established, there is considerable overlap of outcomes between the intermediate and high-risk groups (11) . It is true that good accuracy of the D'Amico risk classification for prediction of BCR after RP was shown also in the present cohort. The c-index of the D'Amico risk classification was 0.730, which was slightly superior to 0.719 of the PRIX score. However, the Kaplan -Meier plots and the calibration plots show the possibility that the PRIX score can present more detailed stratification in the remaining heterogeneity of the intermediate and high-risk patients according to the D'Amico risk classification.
The CAPRA score, representing a scoring system, is a well-known risk prediction model for clinically localized prostate cancer developed from the University of California, San Francisco using data from the Cancer of the Prostate Strategic Urologic Research Endeavor registry encompassing 40 community practices across the USA (4). The CAPRA score is more complex to calculate than the PRIX score. The CAPRA score is a 0 -10 sum of five weighted variables: preoperative PSA level, Gleason score at biopsy, clinical T stage, percentage of positive biopsy cores and age. Assignment of CAPRA score is more detailed, especially in relation to preoperative PSA level and Gleason score, than is the PRIX score. Presently, the CAPRA score has been well validated externally in several cohorts and shown to accurately predict BCR after RP (12 -15) . The c-index in these studies ranged from 0.68 to 0.81, and each compares favorably with the c-index of 0.719 for the PRIX score in the present study. Thus, a future head-to-head comparison between the CAPRA score and the PRIX score would be of interest.
The present study has several limitations. One limitation is the definition of BCR. In the present study, BCR was defined to include not only postoperative PSA elevation of .0.2 ng/ml but also the initiation of salvage treatment. Actually, 30 (29.1%) patients fitting the definition of BCR but with a postoperative PSA of ,0.2 ng/ml underwent salvage treatment. Indeed, a significant number of patients with BCR defined as the low cut-off value of the PSA level do not have a continued increase in PSA level (16) . Patients with a high PRIX score might have tended to receive salvage treatment earlier than patients with a low PRIX score according to the decision of the treating physician, which would have led to bias in the present study. Moreover, BCR is just a surrogate endpoint and does not always translate into systemic progression and prostate cancer death (16, 17) . The reason a surrogate endpoint was used was due to the relatively short follow-up time in the present cohort. With a longer follow-up time, more established endpoints such as clinical progression or cancer-specific or overall survival would be used.
Twenty-six patients undergoing adjuvant therapy or concurrent surgical castration were excluded from the present validation cohort, which is also a limitation that may have introduced selection bias. Patients with a high PRIX score might have been more likely to receive adjuvant therapy or concurrent surgical castration. Consequently, evaluation of patients with a high PRIX score was insufficient in the present study. However, the exclusion of patients undergoing adjuvant therapy was conducted as in other external validation studies because the aim of the present study was to determine the relation between the PRIX score and BCR after RP without the influence of adjuvant therapy.
The present validation cohort also has a unique characteristic in that a high proportion [197 (38.0%)] of the patients underwent NHT before RP. Most of this NHT was administered in an era when it was unclear whether NHT combined with RP was superior to RP alone. The patients undergoing NHT were included in the present cohort because the exclusion of these patients would have resulted in a cohort number too small for validation. However, as was reported in a recent review and meta-analysis, NHT before RP does not provide significant advantage in BCR-free rate over RP alone (18) . Indeed, NHT before RP did not significantly influenced BCR-free rate in the present cohort. Thus, we believe that the high proportion of patients undergoing NHT would have minimal influence on the results of the present study.
In conclusion, the present study showed that the PRIX score can accurately predict BCR after RP with reasonable calibration in Japanese patients undergoing treatment at a single center. The results indicate that the PRIX score might be one option as a prediction model for BCR after RP, even though it was uniquely developed on the basis of correspondence to other prediction models. The present study is only the first validation study of the PRIX score. In the future, additional validation studies in other cohorts and head-to-head comparisons with other predictive models will be required to accurately determine the ability of the PRIX score to predict BCR after RP.
